Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Advenchen Laboratories Nanjing Ltd

Wei Shi

Hongjiang Xu

Yinsheng Zhang

Xiaojin Wang

Jie Wang

Tianxiao Zhao

Xingfeng Ge

Dandan Lu

Wangwei Ao

Yuan Li

Jie Wu

Xushi Liu

Hui Wang

Xueqin Ma

Shuo Chen

Peng Lu

Kai Cao

Li Zhang

Huan Zhang

Jie Ni

Hangzhou Shen

Xiquan Zhang

Ling Yang

Fei Liu

Shanchun Wang

Wei Song

Yizhong Zhu

Yanlong Liu

Hao Yu

Hongmei Gu

Song Tang

Weiwei Feng

Jianqing Zhang

Xujing Tang

Jinan Wang

Bin Wang

Zhongnan Xu

Hongying Zhang

Min Zhou

Yiyan Yao

Yang Li

Limin Liu

Chao Jin

Xiangyi He

Xiayun Chang

Qinglin Wang

Zheyang Wu

Jing Ren

Yadong Miao

Disclosed is a trifluoromethyl-substituted sulfonamide BCL-2-selective inhibitor, in particular disclosed are a compound of formula I, a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition thereof. Also disclosed are the uses of said compound and of a pharmaceutical composition comprising same for treating anti-apoptotic BCL-2-related diseases, such as cancer.

Trifluoromethyl-substituted sulfonamide as BCL-2-selective inhibitor

A drug combination containing a TLR7 agonist. Specifically, a drug combination jointly using the compound of formula I acting as a TLR7 agonist and entecavir for the treatment of hepatitis B virus infection and a use thereof, the drug combination having a good anti-hepatitis B virus infection effect.

Drug combination containing TLR7 agonist

Provided is a compound of formula I or II, a stereoisomer, a tautomer, a geometrical isomer, a solvate, an active metabolite, a hydrate, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and the medical uses thereof in treating diseases benefiting from the capsid protein assembly inhibitor, particularly diseases caused by hepatitis B virus infection.

N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition and uses thereof

A N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, and a pharmaceutical composition and use thereof, specifically relating to a compound as represented by formula I, a stereoisomer, a tautomer, a geometrical isomer, a solvate, an active metabolite, a hydrate, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and a medical use thereof. The medical use comprises the use in treating diseases benefiting from the capsid protein assembly inhibitor, and in particular, diseases caused by hepatitis B virus infection.

N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof

The present application belongs to the field of pharmaceutical chemistry, and relates to a furo[3,4-b]pyrrole-containing BTK inhibitor, and in particular, to a compound of formula (I), a stereisomer or pharmacologically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and use thereof in treating BTK-related diseases.

Furo[3,4-b]pyrrole-containing BTK inhibitor

A N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, and a pharmaceutical composition and use thereof, specifically relating to a compound as represented by formula I, a stereoisomer, a tautomer, a geometrical isomer, a solvate, an active metabolite, a hydrate, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and a medical use thereof. The medical use comprises the use in treating diseases benefiting from the capsid protein assembly inhibitor, and in particular, diseases caused by hepatitis B virus infection. 

Growing community of inventors

Lianyungang, China

Wei Shi